临床研究
ENGLISH ABSTRACT
基线 18F-FDG PET/CT肿瘤内代谢异质性参数在原发性皮肤恶性黑色素瘤中的预后价值
谭千倩
赵莲君
何健
来瑞鹤
作者及单位信息
·
DOI: 10.3760/cma.j.cn321828-20240511-00163
Prognostic value of intratumoral metabolic heterogeneity parameters of baseline 18F-FDG PET/CT in primary cutaneous malignant melanoma
Tan Qianqian
Zhao Lianjun
He Jian
Lai Ruihe
Authors Info & Affiliations
Tan Qianqian
Department of Nuclear Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing 21008, China
Zhao Lianjun
Comprehensive Cancer Centre, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
He Jian
Department of Nuclear Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing 21008, China
Lai Ruihe
Department of Nuclear Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing 21008, China
·
DOI: 10.3760/cma.j.cn321828-20240511-00163
0
0
0
0
0
0
PDF下载
APP内阅读
摘要

目的评估基线 18F-FDG PET/CT肿瘤内代谢异质性参数在原发性皮肤恶性黑色素瘤(CMM)预后中的临床价值。

方法回顾性分析2015年10月至2023年7月于南京大学医学院附属鼓楼医院35例确诊为原发性CMM并行基线 18F-FDG PET/CT检查的患者[男24例、女11例,年龄(66.6±13.1)岁]的临床资料、 18F-FDG PET/CT传统代谢参数[SUV max、肿瘤代谢体积(MTV)、病灶糖酵解总量(TLG)]及PET肿瘤内代谢异质性参数[累积SUV体积直方图AUC(AUC-CSH)、线性回归斜率、SUV max/ SUV mean],以30%、40%、50%、60%、70%、80%SUV max或40%、60%、80%SUV max为阈值勾画的MTV行一般线性回归,其斜率分别为异质性参数-1(HI-1)、异质性参数-2(HI-2);采用SUV阈值分别为2.5,40%、50%、60%、70%SUV max,计算出AUC-CSH、SUV max/SUV mean。采用Kaplan-Meier生存曲线和Cox比例风险模型分析原发灶PET代谢参数对疾病总生存(OS)和无进展生存(PFS)的预后价值。

结果35例患者的中位随访时间为20.0个月,25例(71%)患者病情进展,16例(46%)患者死亡。多因素分析显示,HI-1、HI-2、MTV、SUV max/SUV mean2.5及SUV max是PFS的独立预后危险因素[风险比( HR)(95% CI):0.32(0.13~0.82)、0.32(0.13~0.82)、3.86(1.34~11.12)、4.61(1.33~16.02)、4.06(1.55~10.61),均 P<0.05],SUV max及SUV max/SUV mean2.5是OS的独立预后危险因素[ HR(95% CI):8.04(1.96~32.87)、2.87(1.09~7.51), P值:0.004、0.032]。

结论HI-1、HI-2、SUV max/SUV mean2.5对CMM有预后价值,但AUC-CSH异质性参数预后价值不大。

黑色素瘤;皮肤;正电子发射断层显像术;体层摄影术,X线计算机;氟脱氧葡萄糖F18;预后
ABSTRACT

ObjectiveTo evaluate the clinical prognostic value of intratumoral metabolic heterogeneity parameters of baseline 18F-FDG PET/CT in primary cutaneous malignant melanoma (CMM).

MethodsFrom October 2015 to July 2023, the clinical data of 35 patients (24 males, 11 females, age (66.6±13.1) years) diagnosed with primary CMM who underwent baseline 18F-FDG PET/CT in Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School were retrospectively analyzed. Conventional metabolic parameters (SUV max, metabolic tumor volume (MTV), total lesion glycolysis (TLG)) and PET intratumoral metabolic heterogeneity parameters (area under the cumulative SUV histograms curve (AUC-CSH), linear regression slope, SUV max/ SUV mean) were assessed. Using thresholds of 30%, 40%, 50%, 60%, 70%, and 80% SUV max or thresholds of 40%, 60%, and 80% SUV max to delineate MTV, linear regression was performed, with the slopes being heterogeneity index-1 (HI-1) and heterogeneity index-2 (HI-2), respectively. Using SUV thresholds of 2.5, and 40%, 50%, 60%, and 70%SUV max to calculate AUC-CSH and SUV max/SUV mean. Kaplan-Meier survival curves and Cox proportional hazards models were used to analyze the prognostic value of primary lesion PET metabolic parameters on overall survival (OS) and progression-free survival (PFS).

ResultsThe median follow-up time of 35 patients was 20 months, with 25 patients (71%) experiencing disease progression and 16 patients (46%) deceased. Multivariate Cox regression analysis revealed that HI-1, HI-2, MTV, SUV max/SUV mean2.5, and SUV max were the independent prognostic factors for PFS (hazard rate ( HR) (95% CI): 0.32(0.13-0.82), 0.32(0.13-0.82), 3.86(1.34-11.12), 4.61(1.33-16.02), 4.06(1.55-10.61), all P<0.05), whereas SUV max and SUV max/SUV mean2.5 were the independent prognostic factors for OS ( HR: 8.04(1.96-32.87), 2.87(1.09-7.51), P values: 0.004, 0.032).

ConclusionHI-1, HI-2, and SUV max/SUV mean2.5 have prognostic value for CMM, while the value of AUC-CSH heterogeneity parameters are not significant.

Melanoma;Skin;Positron-emission tomography;Tomography, X-ray computed;Fluorodeoxyglucose F18;Prognosis
Lai Ruihe, Email: mocdef.yabyggjnhrial
引用本文

谭千倩,赵莲君,何健,等. 基线 18F-FDG PET/CT肿瘤内代谢异质性参数在原发性皮肤恶性黑色素瘤中的预后价值 [J]. 中华核医学与分子影像杂志,2025,45(03):154-158.

DOI:10.3760/cma.j.cn321828-20240511-00163

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
皮肤恶性黑色素瘤(cutaneous malignant melanoma, CMM)主要来源于皮肤中的黑色素细胞。2020年全球CMM新发病例32.5万人次,死亡病例5.7万人次 [ 1 ]。早期准确预测以及个体化治疗策略的制定,对提高患者生活品质、延长寿命至关重要。
本课题组前期报道了 18F-FDG PET/CT传统代谢参数SUV max、肿瘤代谢体积(metabolic tumor volume, MTV)、病灶糖酵解总量(total lesion glycolysis, TLG)在黑色素瘤预后中的价值 [ 2 , 3 , 4 ]。目前PET/CT参数预测生存的灵敏度和特异性还不够高,需进一步深度挖掘其他影像学参数,以提高PET/CT参数在恶性黑色素瘤的预后价值。近几年,国外研究利用 18F-FDG PET/CT提出了累积SUV体积直方图AUC(area under the cumulative SUV histograms curve, AUC-CSH)、线性回归斜率、SUV max/SUV mean等异质性参数用于反映肿瘤内代谢异质性。故本研究进一步探讨除了传统PET/CT代谢参数以外的代谢异质性参数在黑色素瘤预后中的价值,并初步研究其最佳勾画阈值。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Sung H , Ferlay J , Siegel RL ,et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 202171(3):209-249. DOI: 10.3322/caac.21660 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
来瑞鹤滕月孙一文. 18 F-FDG PET/CT代谢参数评估原发性皮肤恶性黑色素瘤晚期患者的预后 [J]. 中华核医学与分子影像杂志 2023,43(4):221-225. DOI: 10.3760/cma.j.cn321828-20211104-00384 .
返回引文位置Google Scholar
百度学术
万方数据
Lai RH , Teng Y , Sun YW ,et al. Prognostic value of metabolic parameters measure d by 18 F-FDG PET/CT in patients with primary advanced cutaneous malignant melanoma [J]. Chin J Nucl Med Mol Imaging, 2023,43(4):221-225. DOI: 10.3760/cma.j.cn321828-20211104-00384 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[3]
来瑞鹤滕月赵莲君 基线 18 F-FDG PET/CT评估抗PD-1免疫治疗转移性黑色素瘤患者的预后 [J]. 中华核医学与分子影像杂志 2023,43(2):79-84. DOI: 10.3760/cma.j.cn321828-20210727-00251 .
返回引文位置Google Scholar
百度学术
万方数据
Lai RH , Teng Y , Zhao LJ ,et al. Prognostic value of pretreatment 18 F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD1 immunotherapy [J]. Chin J Nucl Med Mol Imaging, 2023,43(2):79-84. DOI: 10.3760/cma.j.cn321828-20210727-00251 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[4]
来瑞鹤赵莲君孙一文 基线 18 F-FDG PET/CT评估原发性恶性黑色素瘤患者的预后 [J]. 中华核医学与分子影像杂志 2022,42(3):144-148. DOI: 10.3760/cma.j.cn321828-20200915-00345 .
返回引文位置Google Scholar
百度学术
万方数据
Lai RH , Zhao LJ , Sun YW ,et al. Prognostic value of pretreatment 18 F-FDG PET/CT in patients with primary malignant melanoma [J]. Chin J Nucl Med Mol Imaging, 2022,42(3):144-148. DOI: 10.3760/cma.j.cn321828-20200915-00345 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[5]
Pinho DF , King B , Xi Y ,et al. Value of intratumoral metabolic heterogeneity and quantitative 18 F-FDG PET/CT parameters in predicting prognosis for patients with cervical cancer [J]. AJR Am J Roentgenol, 2020,214(4):908-916. DOI: 10.2214/AJR.19.21604 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Liu J , Si Y , Zhou Z ,et al. The prognostic value of 18 F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients [J]. Cancer Imaging, 2022,22(1):32. DOI: 10.1186/s40644-022-00472-4 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Gopal A , Xi Y , Subramaniam RM ,et al. Intratumoral metabolic heterogeneity and other quantitative 18 F-FDG PET/CT parameters for prognosis prediction in esophageal cancer [J]. Radiol Imaging Cancer, 2021,3(1):e200022. DOI: 10.1148/rycan.2020200022 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Liu X , Xiang K , Geng GY ,et al. Prognostic value of intratumor metabolic heterogeneity parameters on 18 F-FDG PET/CT for patients with colorectal cancer [J]. Contrast Media Mol Imaging, 2022,2022:2586245. DOI: 10.1155/2022/2586245 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Wang J , Yu X , Shi A ,et al. Predictive value of 18 F-FDG PET/CT multi-metabolic parameters and tumor metabolic heterogeneity in the progn osis of gastric cancer [J]. J Cancer Res Clin Oncol, 2023,149(16):14535-14547. DOI: 10.1007/s00432-023-05246-4 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Wen D , Liu L , Liang Y ,et al. Prediction of outcomes in patients with local recurrent nasopharyngeal carcinoma: development and validation of a four-factor prognostic model integrating baseline characteristics and [ 18 F ] FDG PET/CT parameters [J]. Eur Radiol, 2023,33(4):2840-2849. DOI: 10.1007/s00330-022-09232-1 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Gu B , Zhang J , Ma G ,et al. Establishment and validation of a nomogram with intratumoral heterogeneity derived from 18 F-FDG PET/CT for predicting individual conditio nal risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma [J]. BMC Cancer, 2020,20(1):37. DOI: 10.1186/s12885-020-6520-5 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Sanli Y , Leake J , Odu A ,et al. Tumor heterogeneity on FDG PET/CT and immunotherapy: an imaging biomarker for predicting treatment response in patients with metastatic melanoma[J]. AJR Am J Roentgenol, 2019,212(6):1318-1326. DOI: 10.2214/AJR.18.19796 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Liu G , Yin H , Cheng X ,et al. Intra-tumor metabolic heterogeneity of gastric cancer on 18 F-FDG PETCT indicates patient survival outcomes [J]. Clin Exp Med, 2021,21(1):129-138. DOI: 10.1007/s10238-020-00659-8 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
程楠张谷青高明. 18 F-FDG PET/CT肿瘤内代谢异质性参数预测肺腺癌EGFR基因突变的价值 [J]. 中华核医学与分子影像杂志 2024,44(1):1-5. DOI: 10.3760/cma.j.cn321828-20220824-00269 .
返回引文位置Google Scholar
百度学术
万方数据
Cheng N , Zhang GQ , Gao M ,et al. Predictive value of intratumoral heterogeneity measured by 18 F-FDG PET/CT for EGFR mutation of adenocarcinoma [J]. Chin J Nucl Med Mol Imaging, 2024,44(1):1-5. DOI: 10.3760/cma.j.cn321828-20220824-00269 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[15]
Liu X , Wang SC , Ni M ,et al. Correlation between 18 F-FDG PET/CT intra-tumor metabolic heterogeneity parameters and KRAS mutation in colorectal cancer [J]. Abdom Radiol (NY), 2022,47(4):1255-1264. DOI: 10.1007/s00261-022-03432-5 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Xu M , Gu B , Zhang J ,et al. Differentiation of cancer of unknown primary and lymphoma in head and neck metastatic poorly differentiated cancer using 18 F-FDG PET/CT tumor metabolic heterogeneity index [J]. Nucl Med Commun, 2024,45(2):148-154. DOI: 10.1097/MNM.0000000000001797 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
来瑞鹤,Email: mocdef.yabylgjnhrial
B

谭千倩:研究实施、论文撰写;赵莲君、何健:统计学分析;来瑞鹤:研究指导、论文修改、经费支持

C
所有作者声明无利益冲突
D
南京鼓楼医院2024年临床研究专项资金 (2024-LCYJ-PY-13)
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号